ACROBiosystems社 NKG2A, a promising target within NK cell-based immunotherapy
The NKG2A/CD94/HLA-E pathway is considered to be an important immune checkpoint for NK cell-based immunotherapeutic strategies. NKG2A is expressed as a heterodimer with CD94. The ligands of NKG2A/CD94 heterodimeric receptors are non-classical MHC class I molecules. Engagement of NKG2A/CD94 receptor with peptide-presenting HLA-E results in the phosphorylation of ITIMs in NKG2A. Phosphorylated ITIMs are responsible for recruiting and activating intracellular phosphatase SHP-1 as well as SHP-2, thus suppressing the activation signals generated by activating receptors such as the T cell receptor (TCR) and NKG2D.
Therefore, disrupting the interaction of NKG2A with its ligands is shown to be effective in enhancing antitumor immune responses.
To accelerate the research and drug development of NK cell-based immunotherapeutic, ACROBiosystems has developed a series of NKG2A/CD94 heterodimer proteins that suitable for immunization, antibody screening and more.
★ Products lists
★ Related products
Click on the column for more information
✔ Homogeneous structure and high purity (>90%) verified by MALS
✔ High Bioactivity
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。